Action News 5: PEP Buddy helps people breathe easier
UC Venture Lab-backed startup aims to help people affected by COPD
A hands-free device developed by researchers at the University of Cincinnati could help the 12.5 million Americans who have chronic obstructive pulmonary disease breathe easier, Action News 5 in Memphis, Tennessee, reported.
PEP Buddy, a UC Venture Lab-backed startup, was created by Muhammad Ahsan Zafar, MD, and Ralph J. Panos, MD.
With COPD, it takes longer for people to get inhaled air out of their lungs. With each breath, extra air is retained in the lungs. This “air stacking” during activities (dynamic hyperinflation) is the primary reason for breathlessness in people with COPD and also leads to decreased oxygen levels.
PEP Buddy gives a gentle back pressure while the user breathes out, which assists in keeping open air tubes in the lungs and preventing them from collapsing. The device also prolongs the exhalation phase and reduces the breathing rate, decreasing the effects of air stacking.
“It’s just simply placed in the mouth, one breath in through the nose, and then out through the device. That resistance to airflow creates the back pressure, which relieves the air trapping and dynamic hyperinflation,” Panos said.
Featured image at top: PEP Buddy device. Photo/PEP Buddy
Innovation Lives Here
The University of Cincinnati is leading public urban universities into a new era of innovation and impact. Our faculty, staff and students are saving lives, changing outcomes and bending the future in our city's direction. Next Lives Here.
Related Stories
The Last Show with David Cooper discusses AI in education with UC’s Joshua Lambert
April 12, 2026
The Last Show with David Cooper, a global news podcast, featured Joshua Lambert, PhD, a professor and biostatistician in UC College of Nursing to discuss his latest research on using artificial intelligence for student advising.
UC enrolls first patients in clinical trial for prosthetic joint infections
April 10, 2026
The University of Cincinnati has enrolled the first patients in Peptilogics’ RETAIN clinical trial, testing an investigational drug for prosthetic joint infections after total knee replacement to reduce repeat surgeries and infection recurrence.
A picture-perfect finish for innovation at CEAS EXPO 2026
April 9, 2026
The CEAS EXPO 2026 brought together UC’s brightest engineers to display their forward-thinking projects, with multispectral camera Kromico earning the 1819 Innovation Award.